Your Notified Body Cannot Always Decide Alone — MDR Article 54 Says So

For most devices under MDR, the notified body's conformity assessment decision is final. For a defined slice of the highest-risk devices, it is not the last word. Article 54 of Regulation (EU) 2017/745 requires the notified body to route its clinical evaluation assessment for certain Class III implantable devices and high-risk active devices to an independent expert panel before it can certify — and manufacturers who first learn this at the review stage lose months they never budgeted for.

Who this actually catches

The scope is narrower than manufacturers often assume, and that precision matters because it decides whether the consultation applies at all. Article 54 targets Class III implantable devices and Class IIb active devices intended to administer and/or remove a medicinal product from the body — infusion systems and comparable drug-delivery devices, not every Class IIb active device on the market. If your device is a Class III implantable device or falls into that specific IIb category, the notified body applies the screening criteria in Annex IX, Section 5.1(c) as part of assessing your clinical evaluation report, and the outcome of that screening — not the notified body's general workload or preference — decides whether an expert panel gets involved.

The three exemptions, precisely

Most of the manufacturers who avoid full consultation do it through one of three routes in Annex IX, Section 5.1(c) — and self-assessing against them accurately, before the notified body forms its own view, is worth the effort.

1. Certificate renewal, no significant change. The application renews a certificate already issued under MDR, and the device has not changed in a way that raises new questions about its clinical evaluation.
2. Same-manufacturer modification. The device modifies one the same manufacturer already markets for the same intended purpose, and the manufacturer has demonstrated to the notified body's satisfaction that the modification does not adversely affect the benefit-risk ratio.
3. Common specification coverage. The clinical evaluation principles for that device type or category are already addressed in a Commission common specification, and the notified body confirms the manufacturer's clinical evaluation complies with it.

The exemption analysis is not a formality to note in the technical file. It is the difference between a certification timeline that holds and one that absorbs months of expert-panel review you didn't plan for. Why the Annex IX 5.1(c) screen belongs in the submission plan, not the appendix

What happens once a panel is involved

When the exemptions don't apply, the notified body notifies the competent authorities and the Commission through the electronic system, accompanied by the clinical evaluation assessment report, and the relevant expert panel screens the case. If it decides full consultation is warranted — typically weighing the device's novelty and any significant change in its benefit-risk profile, or a rise in reported serious incidents for that device group — the panel issues a scientific opinion on the sufficiency of the clinical evidence and the benefit-risk determination. That opinion is not a veto. The notified body must give it due consideration, especially where the panel raises concerns, but the notified body reaches its own conformity assessment decision and may proceed differently — provided it documents a full justification. The Commission compiles an annual overview of exactly those cases for the European Parliament, the Council, and the MDCG, which means a poorly justified deviation does not stay quiet.

Article 54 is not a reason to avoid Class III implantable or high-risk drug-delivery development — it is a reason to plan the clinical evaluation workstream around a reviewer you don't control. Manufacturers who treat the CEAR as a document for their notified body alone, and who leave the Annex IX 5.1(c) exemption analysis until a reviewer asks about it, are the ones who discover the expert panel timeline the hard way. The ones who plan around the equivalence route and the consultation procedure together, as part of one EU MDR & IVDR compliance strategy, are the ones whose certification date holds.